139,237 results match your criteria: "Inflammatory Bowel Disease"

Inflammatory bowel disease (IBD) presents a range of extraintestinal manifestations, notably including oral cavity involvement. The mechanisms underlying oral-gut crosstalk in IBD are not fully understood. Exosomes, found in various body fluids such as saliva, play an unclear role in IBD that requires further exploration.

View Article and Find Full Text PDF

The mesenteric adipokine SFRP5 alleviated intestinal epithelial apoptosis improving barrier dysfunction in Crohn's disease.

iScience

December 2024

Anhui Province Key Laboratory of Basic and Translational Research of Inflammation-related Diseases, Bengbu, China.

Article Synopsis
  • The study investigates the role of secreted frizzled-related protein 5 (SFRP5), an adipokine, in the hypertrophic mesenteric adipose tissue (htMAT) of Crohn disease (CD) patients and its impact on intestinal inflammation.
  • SFRP5 levels were found to be higher in the diseased MAT and it aggregates among intestinal epithelial cells, suggesting a potential protective role against intestinal barrier dysfunction.
  • The findings highlight that SFRP5 may help mitigate apoptosis in epithelial cells triggered by inflammation, offering new insights into treatment strategies for Crohn disease via the mesenteric pathway.
View Article and Find Full Text PDF

Inflammatory bowel diseases (IBDs), primarily encompassing ulcerative colitis and Crohn's disease, represent a challenging spectrum of disorders with a multifaceted pathogenesis. Despite the array of available treatments, a demand for novel therapeutic options persists to achieve remission in a broader patient population. Research findings indicate that relying solely on a single biologic drug may limit future treatment choices, prompting consideration for a more suitable shift from step-up to top-down strategies in certain cases.

View Article and Find Full Text PDF

Increased gastrointestinal bleeding-related mortality during the COVID-19 pandemic.

Therap Adv Gastroenterol

January 2025

F. Widjaja Inflammatory Bowel Disease Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, West Hollywood 90048, CA, USAKarsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Article Synopsis
  • The study analyzes national data on gastrointestinal bleeding (GIB) mortality in the U.S. from 2010 to May 2023, highlighting trends and identifying vulnerable populations.
  • Despite a consistent decrease in GIB deaths from 2010 to 2019, there was a surge in excess mortality during the COVID-19 pandemic, especially among young males aged 19-44.
  • By 2023, GIB-related mortality rates returned to expected levels, indicating a resolution of pandemic-related excess deaths.
View Article and Find Full Text PDF

Efficacy and safety of dual-targeted therapy for inflammatory bowel disease: a retrospective multicenter study in China.

Therap Adv Gastroenterol

January 2025

Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, China.

Article Synopsis
  • The study looked at treating tough cases of inflammatory bowel disease (IBD) using a combination of biologics and small molecules.
  • About 47 patients were analyzed, with 37 showing significant improvement after treatment.
  • Side effects were mostly mild, with only one serious case needing hospitalization, indicating that the combination therapy is both effective and safe.
View Article and Find Full Text PDF

Background: The association between inflammatory bowel disease (IBD) activity and poor sleep quality is reported. However, most research subjectively investigated this issue and lacked long-term follow-up.

Objectives: Our study aimed to investigate the prevalence of sleep disturbance in IBD patients across disease activity and evaluate the long-term correlation between disease activity, sleep quality, and quality of life.

View Article and Find Full Text PDF

Background And Aims: Limited data are available on long-term disease outcomes in elderly-onset (EO) inflammatory bowel diseases (IBD) from well-defined population-based cohorts. Our aim was to analyze incidence, disease course, surgery rates and therapeutic strategies of EO IBD in a prospective population-based cohort.

Methods: EO IBD was defined if diagnosis was established at ≥60years of age.

View Article and Find Full Text PDF

Aim: We evaluated the frequency and severity of COVID-19, and vaccination status, in children with different forms of inflammatory bowel disease (IBD).

Methods: This was a prospective, observational cohort study that used a questionnaire to gather data on the patients' vaccination doses, medication and disease activity. Disease flare was defined as worsening IBD symptoms and changes in medication.

View Article and Find Full Text PDF

Background: The benefit of therapeutic drug monitoring (TDM) and implementation of recommendations from the Selection of Therapeutic Targets in Inflammatory Bowel Disease (IBD, STRIDE) are discussed in the IBD community. We report real-world data in ulcerative colitis patients receiving first-line tumour necrosis factor inhibitor (TNFi) treatment followed by TDM, and assess how implementation of the STRIDE II recommendations might affect clinical practice.

Methods: Adult, biologically naïve UC patients starting TNFi between 2014 and 2021 at Oslo University Hospital were included in a medical chart review study, and data were collected at three and twelve months after the start of treatment.

View Article and Find Full Text PDF

Drug Interaction With Advanced Therapies in Inflammatory Bowel Diseases: A Blind Spot to Tackle.

United European Gastroenterol J

January 2025

Department of Gastroenterology, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris APHP, Paris, France.

View Article and Find Full Text PDF

Editorial: Striving for Equitable Care in Ulcerative Colitis.

Aliment Pharmacol Ther

January 2025

Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

View Article and Find Full Text PDF

Background: Approximately 25% of individuals with inflammatory bowel disease (IBD) concurrently experience immune-mediated inflammatory diseases (IMIDs), while the overall prevalence of these conditions in the general population is 5-7%. Individuals with IBD and concurrent IMIDs tend to have a more aggressive disease profile. We aimed to assess the prevalence of coexisting autoimmune disorders among patients with IBD and their association with inflammatory bowel disease type.

View Article and Find Full Text PDF

Background: To compare the long-term safety and efficacy of Adalimumab (ADA) and Infliximab (IFX) agents in biologic-naive patients with Ulcerative colitis (UC).

Methods: The key focus was on specific outcomes such as the requirement of hospitalization due to UC, colectomy, steroid administration, and severe infections that led to the discontinuation of therapy.

Results: Anti-TNF treatment was initiated in 208 of the 475 patients with ulcerative colitis.

View Article and Find Full Text PDF

Background: Up to 30% of patients with Crohn's disease (CD) will experience a mild disease course. However, there is no consensus definition for mild CD.

Aim: To examine the Simple Endoscopic Score for Crohn's disease (SES-CD) thresholds best associated with low likelihood of long-term disease progression.

View Article and Find Full Text PDF

Clinical guidelines typically endorse conventional therapies such as 5-aminosalicylic acid (5-ASA) as the mainstay of ulcerative colitis management. However, the degree of adoption and application of guideline recommendations by physicians within Asia remains unclear. This study aims to understand the prescribing patterns of 5-ASA and implementation of current guideline recommendations across Asian clinical practice.

View Article and Find Full Text PDF

Background: Ulcerative colitis (UC) is a significant inflammatory bowel disease (IBD) that typically arises from chronic inflammation of the intestinal tract. Report suggest that anti-inflammatory drug plays a crucial role in the protection of UC. The recent study demonstrated that columbianadin has a protective effect against UC induced by dextran sulfate sodium (DSS) in rats through the modulation of HO-1/Nrf2 and TLR4-NF-κB signaling pathways.

View Article and Find Full Text PDF

Inflammatory bowel disease, MASLD, and cardiometabolic risks: Unveiling a new perspective on mortality risk.

Dig Liver Dis

January 2025

College of Integrated Traditional Chinese and Western Medicine, Southwest Medical University, Luzhou City, Sichuan Province, People's Republic of China. Electronic address:

View Article and Find Full Text PDF

Ulcerative colitis (UC), one among other refractory diseases worldwide, has shown an increasing trend of progression to colorectal cancer in recent years. In the treatment of UC, traditional Chinese medicine has demonstrated good efficacy, with a high cure rate, fewer adverse effects, great improvement in the quality of patient survival, and reduction in the tendency of cancerous transformation. It shows promise as a complementary and alternative therapy.

View Article and Find Full Text PDF

Tofacitinib Mitigates the Increased SARS-CoV-2 Infection Susceptibility Caused by an IBD Risk Variant in the PTPN2 Gene.

Cell Mol Gastroenterol Hepatol

January 2025

Division of Biomedical Sciences, School of Medicine, University of California Riverside, Riverside, California, USA. Electronic address:

Background: Coronavirus disease (COVID-19), caused by SARS-CoV-2, triggered a global pandemic with severe medical and socioeconomic consequences. While fatality rates are higher among the elderly and those with underlying comorbidities, host factors that promote susceptibility to SARS-CoV-2 infection and severe disease are poorly understood. Although individuals with certain autoimmune/inflammatory disorders show increased susceptibility to viral infections, there is incomplete knowledge of SARS-CoV-2 susceptibility in these diseases.

View Article and Find Full Text PDF

Background: Tumor necrosis factor (TNF) is a pleiotropic cytokine that plays a critical role in the pathogenesis of immune-mediated diseases including inflammatory bowel disease (IBD). The stability of its mRNA transcript, determined in part by destabilizing sequences in its AAUU repeats (ARE) gene region, is an important regulator of its tissue and systemic levels. A deletion in the ARE region of the gene resulted in IBD and arthritis in mice and pigs, supporting a critical role for the cytokine in human IBD and several human arthritides.

View Article and Find Full Text PDF

Pregnancy With a Stoma is Feasible, Though Associated With Manageable Complications.

Inflamm Bowel Dis

January 2025

Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, 9713GZ, Groningen, The Netherlands.

Background: Inflammatory bowel disease (IBD) is often diagnosed in young adults, and therefore frequently coincides with pregnancy. Patients may require surgery that includes (temporary) stoma placement. Literature on the occurrence of stoma-complications during pregnancy and the effect on pregnancy outcomes is limited.

View Article and Find Full Text PDF

Background: Inflammatory Bowel Disease (IBD), comprising Crohn's Disease (CD) and Ulcerative Colitis (UC), is a complex condition with diverse manifestations; recent advances in multi-omics technologies are helping researchers unravel its molecular characteristics to develop targeted treatments.

Objective: In this work, we explored one of the largest multi-omics cohorts in Inflammatory Bowel Disease, the Study of a Prospective Adult Research Cohort (SPARC IBD), with the goal of identifying predictive biomarkers for CD and UC and elucidating patient subtypes.

Design: We analyzed genomics, transcriptomics (gut biopsy samples), and proteomics (blood plasma) from hundreds of patients from SPARC IBD.

View Article and Find Full Text PDF

Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

View Article and Find Full Text PDF